Skip to main content
. Author manuscript; available in PMC: 2015 Dec 23.
Published in final edited form as: Hepatology. 2014 May 27;60(1):98–105. doi: 10.1002/hep.27095

Table 2.

Association between HCV Genotypes and Risk of Incident Cirrhosis (column 2) and Hepatocellular Cancer (column 3) – Results of Multivariable Cox Regression Analyses

Characteristics Adjusted Hazard Ratio (95% confidence Interval)
Incident Cirrhosis Incident HCC
HCV genotype
 1 1.0 1.0
 2 0.68 (0.64, 0.73) 0.55 (0.47, 0.63)
 3 1.30 (1.22, 1.39) 1.80 (1.60, 2.03)
 4 0.94 (0.78, 1.14) 0.99 (0.68, 1.45)
Demographics
Age 1.03 (1.02, 1.03) 1.07 (1.06, 1.08)
Gender
 Female 1.0 1.0
 Male 1.16 (1.03, 1.32) 2.78 (1.77, 4.38)
Race
 White 1.0 1.0
 African American 0.58 (0.56, 0.61) 0.73 (0.66, 0.79)
 Hispanic 1.28 (1.19, 1.37) 1.53 (1.34, 1.74)
 Others 0.89 (0.79, 1.05) 0.86 (0.63, 1.19)
 Missing 0.79 (0.73, 0.86) 0.82 (0.69, 0.98)
Period of Service
 World War I/II 1.0 1.0
 Vietnam 1.29 (1.16, 1.44) 1.38 (1.15, 1.66)
 Post-Vietnam 1.12 (0.98, 1.29) 0.95 (0.74, 1.22)
Clinical factors
Yes of HCV diagnosis
 2000–2002 1.0 1.0
 2003–2005 1.09 (1.04, 1.14) 1.24 (1.14, 1.36)
 2005–2009 1.36 (1.27, 1.46) 1.94 (1.68, 2.24)
Diabetes
 No 1.0 1.0
 Yes 1.34 (1.26, 1.42) 1.34 (1.21, 1.49)
Alcohol use
 No 1.0 1.0
 Yes 1.16 (1.12, 1.20) 1.21 (1.12, 1.30)
HIV co-infection
 No 1.0 1.0
 Yes 1.09 (1.00, 1.20) 0.91 (0.75, 1.13)
Body mass index
 <18.5 1.0 1.0
 18.5 – 24 1.05 (0.86, 1.27) 1.18 (0.82, 1.72)
 25 – 29 1.18 (0.97, 1.43) 1.14 (0.78, 1.64)
 ≥30 1.42 (1.18, 1.73) 1.21 (0.83, 1.75)
Antiviral treatment
 No treatment 1.0 1.0
 Sustained response 0.74 (0.68, 0.81) 0.36 (0.29, 0.46)
 No response 1.99 (1.89, 2.10) 1.30 (1.16, 1.46)
HHS Vulnerability Disclosure